INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

INOVIO (NASDAQ:INO) will release fourth quarter and full year 2025 financial results after market close on March 12, 2026.

Rhea-AI Summary

INOVIO (NASDAQ:INO) will release fourth quarter and full year 2025 financial results after market close on March 12, 2026.

Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss results and provide a general business update; the webcast will be archived for 90 days.

Argus Mar 6 session

+3.57% close to close Open Argus

Details

News Market Reaction – INO

On Mar 6, the first trading day after this news, INO closed 3.57% above the previous close.

Data tracked by StockTitan Argus for the Mar 6 session.

Market Context

This announcement sets March 12, 2026 as the date for INOVIO’s Q4 and full-year 2025 results, with a...

Analysis

This announcement sets March 12, 2026 as the date for INOVIO’s Q4 and full-year 2025 results, with a 4:30 p.m. ET call and a 90-day replay. It follows recent clinical, regulatory, and financing-related updates, including BLA review progress and warrant amendments. Investors may focus on upcoming metrics such as revenue trends, cash resources, and commentary on programs like INO-3107 and the glioblastoma collaboration when evaluating the broader outlook.

Key Figures

Earnings release date: March 12, 2026 Conference call time: 4:30 p.m. ET Webcast replay window: 90 days

Earnings release date

March 12, 2026

Q4 and full-year 2025 results release after market close

Conference call time

4:30 p.m. ET

Scheduled earnings call and webcast

Webcast replay window

90 days

Archived replay availability after the earnings call

Historical Context

5 past events · Latest: 2026-03-04

5 events

1. 2026-03-04

   Clinical collaboration

   24h Move

   +3.0%

   Announced Phase 2 INSIGhT trial combo for glioblastoma with Akeso.

2. 2026-02-12

   Conference participation

   24h Move

   -1.9%

   Outlined upcoming scientific and investor conference presentations and meetings.

3. 2025-12-29

   Regulatory update

   24h Move

   -24.4%

   FDA accepted INO-3107 BLA and highlighted an accelerated approval review issue.

4. 2025-12-19

   Inducement grant

   24h Move

   -1.3%

   Reported equity inducement option grant to a new employee under plan.

5. 2025-11-18

   Investor conferences

   24h Move

   -4.5%

   Planned December investor conference appearances and one-on-one meetings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PLYMOUTH MEETING, Pa., March 5, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its fourth quarter and full year 2025 financial results will be released after the market close on March 12, 2026. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update.

The live webcast will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts. The webcast will be archived and available for replay for 90 days following the event.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancers, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026-302705847.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will INOVIO (INO) report its Q4 and full year 2025 financial results?

INOVIO will release Q4 and full year 2025 results after market close on March 12, 2026. According to INOVIO, a live conference call and webcast will follow at 4:30 p.m. ET to review the results and provide a general business update.

What time is INOVIO's (INO) conference call and webcast on March 12, 2026?

The live conference call and webcast will begin at 4:30 p.m. ET on March 12, 2026. According to INOVIO, the event follows the after-market release of fourth quarter and full year 2025 financial results and will include a business update.

How can investors access INOVIO (INO) webcast for the March 12, 2026 earnings call?

Investors can access the live webcast via the company's investor site at the events and presentations page. According to INOVIO, the webcast link will be available at http://ir.inovio.com/events-and-presentations/default.aspx and is the primary access point for the listen-only event.

Will INOVIO (INO) offer a replay of the March 12, 2026 webcast and for how long?

Yes, INOVIO will archive the webcast and make it available for replay for 90 days after the event. According to INOVIO, the archived recording will be accessible on the investor events and presentations page for later review.

Will there be a Q&A session during INOVIO's (INO) March 12, 2026 webcast?

Yes, the webcast is listen-only but will include a live Q&A with analysts after the presentation. According to INOVIO, analysts will be able to ask questions during the call following the prepared remarks and business update.